Furthermore, our data suggest that HIF-2α targeting, particularly in combination with ICB, could be expanded as a strategy to regulate immunosuppression across various solid tumors, providing a promising approach to enhance anti-tumor immune responses in glioma. This evidence concerns the gene EPAS1 and neoplasm.